Skip to main content
Premium Trial:

Request an Annual Quote

Prometheus, Bayer Schering in Cancer PGx Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories said today that it has struck a license and development agreement with Bayer Schering Pharma for oncology diagnostics that could net Prometheus as much as $160 million.

Under the non-exclusive agreement, which includes up-front and milestone payments, San Diego-based Prometheus will use its oncology diagnostic platform, which measures expression and activation of specific cancer pathways, to develop oncology tools that could be used to advance and personalize novel cancer therapeutics.

A functional pathway analysis using Prometheus' technology "could allow for a comprehensive analysis of the tumor, patient stratification, and efficacy predictability of individual targeted cancer therapeutics as well as most effective treatment combinations," Bayer Schering Pharma's Head of Global Drug Discovery, Andreas Busch, said in a statement. "Developing such a diagnostic tool constitutes a significant step towards personalized medicine in cancer treatment and we are convinced this will increasingly become the standard of clinical care in oncology."

Prometheus said that the deal could be worth up to $160 million if all drug candidates are successfully developed and obtain regulatory approval.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.